Category
57 research guides in Thyroid.
The deiodinase enzymes - DIO1, DIO2, and DIO3 - decide how much active thyroid hormone reaches tissue, independent of what the thyroid gland produces. This guide explains how the three enzymes work, what impairs them in chronic illness, and why deiodinase dysfunction produces hypothyroid signs with a normal-looking thyroid panel.
Tapering off Wilson's WT3 protocol after reaching the temperature target is a defined research-community process. Completion criteria, the 7.5 mcg taper schedule, what to monitor during weaning, and what happens if endogenous T3 production hasn't returned by protocol end.
Plateau on Wilson's WT3 protocol - reaching target temperature briefly then regressing, or never reaching target despite continued titration - is a discussed pattern in the bioenergetic research community. The T3 to T2 conversion bottleneck, reverse T3 re-accumulation, selenium and iron confounders, and the T3+T2 enhanced-protocol response.
When T3 doesn't produce the expected response, the bioenergetic research community has six framework explanations: dose too low, reverse T3 dominance, T3 to T2 conversion bottleneck, adrenal dysfunction, iron deficiency, autoimmune flare. The diagnostic framework and what research subjects do about each.
Why most labs report total T3 (bound + free) by default, what total T3 actually measures, thyroid-binding globulin considerations, estrogen effects on TBG, what to ask the lab for, and how to interpret total T3 when free T3 isn't available.
Slow release T3 absorption is meaningfully affected by food, calcium, iron, coffee, and soy. The research-community conservative recommendation: empty stomach, 60 minutes before food or 4 hours after. Mechanism, the specific interactions that matter, and when to make exceptions.
Morning headache on slow release T3 has a specific HPA-axis explanation - T3 sensitizing the cortisol awakening response in research subjects with adrenal dysfunction. The cortisol-crash pattern, dosing-timing adjustments, and the adrenal-cofactor framework the bioenergetic research community uses.
Missing a slow release T3 dose has a specific research-community decision tree: less than 4 hours late, take it; 4-12 hours late, judge by next-dose proximity; more than 12 hours late, skip and resume normal schedule. The pharmacokinetic rationale for never doubling up.
Insomnia on slow release T3 has two distinct patterns: classical T3 insomnia (overnight metabolic activation prevents sleep onset) and inverse T3 insomnia (T3 corrects cortisol-flatness so sleep IMPROVES). Mechanism, timing adjustments, and the diagnostic question that distinguishes the two patterns.
Heart palpitations on T3 have specific pharmacokinetic causes - the chronotropic effect of acute serum T3 surges. Mechanism, why SR-T3 reduces palpitations relative to immediate-release Cytomel, the magnesium-iron-cofactor angle, and when palpitations are a signal to stop the protocol entirely.
Anxiety on slow release T3 has specific mechanistic causes - beta-adrenergic sensitization from rapid serum peaks, HPA-axis activation, catecholamine substrate competition. Research-community framing of why the anxiety pattern occurs, why SR-T3's flatter curve reduces it relative to immediate-release Cytomel, and the dose-adjustment patterns research subjects commonly use.
The research-context starting dose for slow release T3 - the Wilson's WT3 lineage starts at 7.5 mcg every 12 hours; maintenance-protocol research subjects often start at 15-25 mcg once daily. Body-weight considerations, the titration tempo, and when to start lower.
Split dosing of slow release T3 - dividing the total daily dose into two or more administrations - is a research-community pattern with specific indications. The 12-hour Wilson's pattern, alternative split patterns, the pharmacokinetic argument, and when to switch from single-daily to split.
Morning vs evening slow release T3 dosing has a specific HPA-axis answer. Why most research subjects on single-daily SR-T3 dose in the morning to align with cortisol awakening, and the cases where evening or split AM+PM dosing is the research-community preference.
The complete 2026 research guide to slow release T3 dosing, titration, timing, and troubleshooting. Starting dose, titration schedule, morning vs evening timing, food and absorption, missed-dose protocol, the six explanations for T3 non-response, and the troubleshooting framework the bioenergetic research community has converged on for the SR-T3 protocol.
Free T3 lab reference range vs the symptom-resolution range research subjects target. The bioenergetic research framework's upper-third positioning, the comparison to symptom resolution, and what optimal Free T3 means in cyclic vs maintenance protocols.
The Wilson's T3+T2 enhanced protocol extends Dr. Denis Wilson's original cyclic T3 framework with paired T2 dosing. By supplying T3 for receptor activation and T2 for direct mitochondrial activation simultaneously, the enhanced protocol bypasses both the T4→T3 and T3→T2 conversion bottlenecks. Complete breakdown of the rationale, dose pairings, and how the 1:1 T3+T2 ratio fits into existing Wilson's titration schedules.
The complete 2026 research guide to 3,5-T2 (3,5-diiodo-L-thyronine) - the lesser-known thyroid metabolite that bypasses nuclear receptors and binds directly to mitochondrial cytochrome c oxidase. Mechanism, dose ranges, TSH safety profile, and why it's gaining attention in chronic-illness research.
Wilson's Protocol solved the T4→T3 conversion problem. The body still has to perform a second conversion - T3 to T2 - using the same deiodinase enzymes that the first step depends on. This article explains why the T3 protocol plateau many chronic-illness patients hit is often a T2 production failure, and what that means for next-generation T3+T2 research.
The complete 2026 comparison of T2, T3, and T4 thyroid hormones - hormone structure, receptor affinity, mechanism, half-life, TSH suppression potency, use cases, and why bioenergetic researchers increasingly argue all three are needed for complete metabolic signaling.
The Scorch Protocol is the most-discussed T2-focused research framework in the metabolic-research community. Complete breakdown of the protocol's dose ranges, cycling rationale, lipid-cleansing mechanism, TSH safety profile, and how it compares to other T2 research approaches.
The complete 2026 research guide to the Ray Peat protocol - the bioenergetic framework that pairs slow-release T3, anti-serotonin compounds, pregnenolone and progesterone, methylene blue, and a metabolic-rate-supportive diet. Mechanism, compounds, controversies (including the fasting debate), and how the framework integrates with modern T3+T2 research.
A careful re-examination of Ray Peat's anti-fasting argument with the missing piece - 3,5-T2 and the mitochondrial mechanism Peat's framework predates. Where Peat's cortisol argument holds, where T3 replacement modifies it, and where T2 supplementation reframes it entirely.
The Ray Peat-aligned thyroid stack the bioenergetic-research community converges on - sustained-release T3 plus 3,5-T2 plus cyproheptadine - explained from mechanism to sourcing. Why each component matters, how they integrate, and where to find research-grade reference standards with clean excipient profiles.
Cynomel and Cynoplus - the Mexican liothyronine products that became the gold-standard cheap-T3 source for the bioenergetic-research community over the 2000s and 2010s - have become harder to source consistently. Mechanism overview, the Grossman's manufacturing history, supply chain variability, and the case for sustained-release T3 (SR-T3) as the modern research-grade alternative.
Ray Peat opposed fasting on cortisol-suppression grounds. A growing subset of bioenergetic researchers argue that T3 replacement neutralizes the cortisol argument and unlocks fasting's autophagy and mitochondrial-biogenesis benefits. The mechanistic case for strategic fasting paired with sustained-release T3.
The 2026 sourcing guide for liothyronine (T3) - including Cytomel from standard pharmacies, sustained-release SR-T3 from compounding pharmacies, telehealth options, international sourcing, and research-grade reference standards. Pricing, requirements, quality markers.
The definitive 2026 guide to sustained release T3 (SR-T3, also called slow release T3 or SRT3). Pharmacokinetics, dosing protocols, compounding-pharmacy sourcing, side-effect comparison vs Cytomel, and what to look for in a clean-excipient formulation.
Everything researchers and patients need to know about reverse T3 (rT3) in 2026 - what it is, why it rises, how to interpret your free T3 to reverse T3 ratio, and the protocols most commonly used to clear rT3 dominance and restore active T3 signaling.
The definitive 2026 comparison of natural desiccated thyroid (NDT) vs sustained-release T3 vs Cytomel vs levothyroxine. Composition, pharmacokinetics, dosing, FDA status, side-effect profiles, and which formulation fits which patient pattern.
An overview of Georgi Dinkov's bioenergetic framework for T3 research - the Ray-Peat-inspired model that treats T3 as the central anti-stress, pro-respiration hormone. Dosing approaches, T3-only vs T4/T3 ratios, cyclic dosing, and the rationale behind sustained-release T3.
Everything researchers need to know about obtaining slow release T3 liothyronine - compounding options, research-grade sources, and what to expect. Updated for 2026.
Comparing natural desiccated thyroid (Armour, NP Thyroid, ERFA) with slow release T3. T3:T4 ratios, consistency issues, and why some patients do better on pure sustained-release T3.
Comparing slow release T3 (SRT3) with instant release liothyronine. Blood level stability, dosing frequency, side effects, and why sustained-release T3 may be superior for thyroid optimization.
A head-to-head comparison of slow release T3 (SRT3), Cytomel (brand liothyronine), and compounded sustained-release T3. Pharmacokinetics, cost, availability, and which patients benefit from each.
Menopause and thyroid dysfunction share nearly identical symptoms. Learn why Canadian women over 40 need to check T3 levels and how slow release T3 can help.
A detailed guide to the Wilson's Temperature Syndrome WT3 protocol using slow release T3. Cycling, dosing, temperature monitoring, and what researchers need to know.
Brain fog, poor memory, and slow thinking on levothyroxine? Low cellular T3 impairs brain function. Learn how slow release T3 helps Canadian thyroid patients think clearly again.
Losing hair despite thyroid treatment? Low cellular T3 is often the missing link. Learn how slow release T3 supports hair follicle recovery for Canadian thyroid patients.
How adrenal fatigue sabotages thyroid function and why addressing cortisol is essential before optimising T3. The cortisol-thyroid axis explained for Canadians.
Still exhausted, gaining weight, and foggy on levothyroxine? Learn why T4-only therapy fails many Canadians and how adding slow release T3 can restore thyroid function.
Everything you need to know about Wilson's Temperature Syndrome (WTS) - the chronic low-temperature condition linked to T3 deficiency. Symptoms, diagnosis, and the slow-release T3 protocol.
Understand the critical difference between T3 and T4 thyroid hormones, why T4-only medication fails many patients, and how adding T3 can restore metabolic function.
If you're hypothyroid and struggling to lose weight despite diet and exercise, low T3 may be the missing piece. Learn why T4-only medication isn't enough for metabolic recovery.
High reverse T3 (rT3) blocks active T3 at the cellular level, causing hypothyroid symptoms even with normal labs. Learn how to test for it and what to do about it.
Compare sustained-release T3 (SRT3) with instant-release Cytomel (liothyronine). Understand pharmacokinetics, side effects, and why many patients switch to slow release.
Your TSH is 'normal' but you're exhausted, gaining weight, and losing hair. Here's why TSH alone is a terrible measure of thyroid function and what tests you actually need.
Many Hashimoto's patients remain symptomatic on levothyroxine alone. Research shows autoimmune thyroiditis impairs T4-to-T3 conversion, making direct T3 supplementation essential.
A consistently low body temperature below 98.6°F is one of the most reliable indicators of low T3 and thyroid dysfunction. Learn how to track it and what it means for your health.
If you're on thyroid medication but still crushing exhausted, your T3 levels may be the problem. Learn why levothyroxine alone can't fix thyroid fatigue and what works better.
A practical guide to T3 dosing - from choosing your starting dose to titration protocols, temperature monitoring, and knowing when you've reached your optimal level.
Research shows a striking overlap between fibromyalgia symptoms and low T3 thyroid function. Many fibromyalgia patients improve dramatically when T3 levels are optimized.
CFS/ME patients frequently show impaired thyroid hormone conversion. Research suggests T3 supplementation may address the metabolic dysfunction at the heart of chronic fatigue.
Selenium is the most critical mineral for thyroid hormone conversion. Without adequate selenium, your body cannot efficiently convert T4 into active T3 - no matter how much levothyroxine you take.
T3 is the master switch for your metabolism. Understand exactly how this thyroid hormone controls your metabolic rate, body temperature, energy production, and body composition.
Subclinical hypothyroidism affects millions who fall in the diagnostic gap - TSH slightly elevated, T4 'normal,' but symptoms are very real. Learn why early treatment with T3 may prevent progression.
A comprehensive deep dive into why Slow Release T3 (SRT3) is the preferred choice for metabolic researchers and clinical thyroid studies. Explore dosing protocols, mechanisms of action, and the advantages of sustained-release formulations.